All News

An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.

A recent study identified a new biomarker in colorectal cancers that may assist in early detection of the disease.

Cancer Network spoke with Curtis Pickering, PhD, about prognostic gene expression signatures for HPV-positive oropharyngeal and cervical cancers.

Researchers conducted the first population-based study of an unselected MTC cohort compared with the general population.

Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.

Cancer Network spoke with Dr. Michael Holick about the role of and effectiveness of vitamin D in cancer prevention.

Researchers tested the combination of dabrafenib and trametinib in a phase II trial of patients with biliary tract cancer and BRAF V600E mutations.

An analysis found that tumor response as assessed using modified RECIST criteria is an independent predictor of overall survival in hepatocellular carcinoma patients.

Dr. Manson discusses the results of the recently published VITAL study that tested whether vitamin D or omega-3 supplements could be effective for primary prevention of cancer and cardiovascular disease.

The findings of a systematic review may help standardize reflectance confocal microscopy terminology, which is used to describe non-melanocytic lesions.

Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.

The highest rates of excess body weight–associated cancer were found in the South and Midwest, Alaska, and the District of Columbia, according to the study.

Cancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.

Cancer Network spoke with Dr. Chuan-Hsiang Huang about his lab’s research on Ras-ERK protein interactions within cancer cells.

Cancer Network spoke with Dr. Rachel Karchin about the contemporary search for cancer-driving gene mutations.

A study shows patients in the placebo group of clinical trials testing against targeted and immunotherapy cancer drugs may experience a high rate of grade 3/4 adverse events.

The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.

Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?

Cancer Network speaks with Dr. Pavel Sumazin about his ongoing efforts to further understand how lncRNA influence genes with known function in cancers.

Cancer Network speaks with Eduardo Eyras, PhD about the emerging roles of RNA splicing variants in cancer treatment.

Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.

Researchers in England investigated whether risk for suicide was elevated in cancer patients, and which cancer types might have the greatest risk.

Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.

Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.

Survey results published in JAMA Network Open looked at motivating factors behind patient travel and how far they were willing to go for treatment.

Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.

Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.

Professor Lana E. Kandalaft, PharmD, PhD spoke with Cancer Network about the next generation of cancer immunotherapy.

A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.